Bio

Thomas Eklund joined Impilo in 2017 and currently serves as a board member for Impilo’s portfolio company Immedica Pharma AB. Thomas serves as an independent advisor, investor and board member in Life Science companies. Thomas has an MBA from Stockholm School of Economics and was CEO at Investor Growth Capital 2002-2015 and partner at AACP 2000-2002. During the period 1992-2000 Thomas worked at Handelsbanken Corporate Finance within Life Science. Thomas currently serves as chairman for Immedica Pharma AB, Mabtech AB and Sedana Medical AB. Thomas is a board member of Swedencare AB and Boule Diagnostic AB. Thomas has been head of investments and board member at Swedish Orphan, Carmel Pharma AB, Entific Medical Systems AB and Vårdapoteket AB.